Walter Jonat

TL;DR: The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.

TL;DR: The age-specific benefits of polychemotherapy appeared to be largely irrespective of menopausal status at presentation, oestrogen receptor status of the primary tumour, and of whether adjuvant tamoxifen had been given.

TL;DR: An interdisciplinary expert panel of clinical oncologists and of specialists in metabolic bone diseases assessed the widespread evidence and information on the efficacy of BP in the metastatic and nonmetastatic setting, as well as ongoing research on the adjuvant use of BP and recommends amino-bisphosphonates for patients with metastatic bone disease from breast cancer and zoledronic acid for Patients with other solid tumours as primary disease.

TL;DR: Goserelin offers an effective, well-tolerated alternative to CMF in premenopausal patients with ER-positive and node-positive early breast cancer and side effects related to estrogen suppression were initially higher with goserelin, but when gose Relin treatment stopped, reduced to a level below that observed in the CMF group.

TL;DR: This study confirms that capecitabine achieves a high tumor control rate in heavily pretreated patients with metastatic breast cancer and should be considered the reference treatment in this setting based on consistently high efficacy and good tolerability.